News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3125last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Investing.com2d agoneutral
While biotech bets swing on trial data, this dividend payer gained 72% since 2024Business Wire3d agoneutral
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)GuruFocus.com8d agoneutral
Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Phase 3 ...MT Newswires10d agoneutral
Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC SaysMT Newswires10d agobullish
UBS Adjusts Price Target on Biogen to $300 From $270, Keeps Buy RatingMT Newswires10d agobullish
RBC Raises Price Target on Biogen to $272 From $256, Keeps Outperform RatingGlobeNewswire10d agoneutral
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026Simply Wall St.46d agoneutral
How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease DataSimply Wall St.46d agoneutral
Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?Insider Monkey54d agobullish
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades - Which Pharma Stock Has More Upside?MarketBeat55d agoneutral
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience